Beijing Errui Xinyue Technology

About Beijing Errui Xinyue Technology

Beijing Errui Xinyue Technology (北京尔瑞鑫悦) is a Chinese biotechnology company, set up in 2021, focused on early diagnostic technology and products for neurodegenerative diseases. Its vision is to apply exosome technology to protect life and health, and its platform is based on automated, targeted enrichment of exosomes from blood.

Using this platform, its wholly owned subsidiary Beijing Kaixiang Hongkang Biotechnology developed a plasma exosome alpha-synuclein test kit (magnetic particle chemiluminescence immunoassay, trade name Paliming) for the assisted diagnosis of Parkinson's disease. It enriches neuron-derived exosomes from peripheral blood and measures alpha-synuclein, and was approved by the Beijing drug regulator, which makes it described as the world's first plasma-exosome-based in vitro diagnostic for Parkinson's disease. Registration data report sensitivity of about 91 percent and specificity of about 93 percent against current clinical diagnosis.

The company is also advancing blood-based assisted diagnostic products for Alzheimer's disease and mild cognitive impairment, and states that more than ten products are in development and registration. It has its own research and production environment able to take class I, II and III products from development through registration to manufacture, and a core team with an average of more than fifteen years of operating experience at leading international pharmaceutical companies.

The company develops and sells in vitro diagnostic kits to hospitals and clinical laboratories, in the neurodegenerative disease diagnostics market, where early blood-based detection can replace invasive or late-stage clinical diagnosis.